In general, the incidence of treatment-related adverse events (AEs) was lower in the patients treated with MONO than in those treated with COMB; however, no phase III trials have directly compared MONO and COMB, and whether MONO or COMB should be administered to NSCLC patients with high PD-L1 expression is open to investigation. Here, CD274 is linked to non-small cell lung carcinoma.